Menopause and Hormone Optimization at Liondale Medical

Perimenopause and menopause are not just hot flashes and disrupted sleep. They are a systemic hormonal shift that affects energy, cognition, cardiovascular risk, bone density, body composition, and mood, often in ways that standard annual physicals do not address. At Liondale Medical on the Upper West Side, Dr. Bissoon approaches hormone optimization as a physician-led, lab-driven process. The goal is not to restore 25-year-old hormone levels. It is to find the levels at which your individual physiology functions best, support them with precision, and monitor the response over time.

Some patients come in thinking they need one prescription. Most need a real workup first. Hormones interact with thyroid function, stress hormones, insulin resistance, sleep quality, body composition, and the way a patient is actually feeling day to day. That is why this process starts with data, not guesswork. If you are looking at menopause support in the broader context of longevity medicine, you can also review our concierge longevity medicine page or contact the office through Liondale Medical.

What Changes During Perimenopause and Menopause

Estrogen and progesterone decline, but not on a neat schedule. One woman may move through perimenopause over two years. Another may spend eight years in a stop-start transition that feels impossible to predict. Follicle-stimulating hormone, or FSH, rises as the pituitary tries to stimulate ovaries that are becoming less responsive. Testosterone often declines too. That part gets ignored in a surprising number of routine menopause discussions, even though it can affect libido, motivation, recovery, and muscle maintenance.

The symptom list is broader than most patients are told. Yes, vasomotor symptoms matter: hot flashes, night sweats, sudden heat intolerance, sleep disruption. But the neurologic and metabolic changes are often what drive people to seek help. Brain fog. Word retrieval issues. Reduced focus. Mood swings that feel out of character. Anxiety that seems to come out of nowhere. Lower exercise tolerance. A body composition shift that no longer responds to the same diet and training habits. Vaginal dryness and urinary symptoms may show up. Joint pain may show up. Bone density changes may develop quietly before a woman realizes what is happening.

The cardiovascular side deserves more attention than it usually gets. After menopause, lipid patterns can worsen, insulin sensitivity can change, and vascular risk starts to look different. That does not mean every symptom is hormonal. It does mean hormones belong in the conversation when a woman in her 40s, 50s, or early 60s says, plainly, "I do not feel like myself anymore." Too many patients are told they are stressed, busy, or just getting older. Sometimes that is part of the story. Sometimes the hormonal component is identifiable, measurable, and worth treating.

That distinction matters because not every patient needs hormone therapy, and not every patient who is suffering should be dismissed. Good menopause care sits between those two mistakes.

How Liondale Approaches Hormone Evaluation

At Liondale, evaluation goes beyond a quick FSH check and a generic discussion of symptoms. The baseline panel is meant to show the whole hormonal picture, not a thin slice of it. That usually includes sex hormones such as estradiol, total testosterone, free testosterone, progesterone where relevant, and DHEA-S. Thyroid function matters too, so the workup often includes TSH, free T3, and free T4. Thyroid dysfunction is common in this age group, and it can mimic or amplify menopause symptoms.

Stress physiology matters. Cortisol pattern affects sleep, recovery, and the way patients tolerate hormonal shifts. Metabolic markers matter too because glucose regulation and insulin resistance often worsen as estrogen declines. That is why baseline testing may include glucose, insulin, and HbA1c. A lipid panel is also important. Menopause changes cardiovascular risk, and the starting point matters before any treatment decision is made.

Where relevant, Dr. Bissoon also looks at SHBG, or sex hormone binding globulin. That number helps explain how much free hormone is actually available to tissues. A patient can have a total hormone value that looks acceptable on paper and still have a free hormone picture that does not match her symptoms. That is one reason symptom-only prescribing can go wrong. So can lab-only prescribing. The point is to line up the clinical picture with the data.

• Sex hormones: estradiol, total testosterone, free testosterone, progesterone where relevant, DHEA-S.
• Thyroid markers: TSH, free T3, free T4.
• Cortisol pattern: because adrenal function affects symptom burden and hormone metabolism.
• Metabolic markers: glucose, insulin, HbA1c.
• Lipid panel: to understand the cardiovascular baseline in peri- and post-menopause.
• SHBG when relevant: to clarify free hormone availability.

This is not testing for the sake of testing. It is the baseline used for follow-up. If you later feel better, worse, or only partly improved, the numbers help explain why. Without that foundation, clinicians often underdose, overdose, or miss the real driver completely. That is not precision medicine. It is guesswork with a prescription pad.

It also gives Dr. Bissoon something many menopause visits never establish: your own baseline before treatment begins. That matters because "normal" on a reference range is not the same thing as normal for you. A woman may have labs that sit inside a broad laboratory range and still show a pattern that fits her symptoms, timing, and physiology. The point of the workup is to define that pattern before any hormone is prescribed.

Bioidentical Hormone Therapy - What It Is and What It Isn't

Bioidentical hormone therapy, or BHRT, uses hormones with the same molecular structure as those produced by the human body. In practice, that usually means estradiol, progesterone, and in selected cases testosterone. Delivery options may include topical gels, creams, transdermal patches, pellet implants, and in some cases oral medications. Each option has tradeoffs. A patch may be simple and steady. A cream may allow dose flexibility. A pellet may appeal to patients who want less frequent dosing, but it is not as easy to fine-tune once placed. The right delivery method depends on labs, symptoms, response pattern, medical history, and patient preference.

One of the most confusing parts of this conversation is the legacy of the Women's Health Initiative. The WHI did not study what most patients mean when they ask about modern bioidentical hormone therapy. It used conjugated equine estrogen and medroxyprogesterone acetate, not bioidentical estradiol and progesterone. That difference matters. It does not erase risk, and it does not mean every modern regimen is safe by default. But it does mean patients deserve a more accurate discussion than the old blanket message that all hormone therapy should be viewed through the same lens.

Dr. Bissoon is direct about the complexity here. BHRT is not a free pass. The evidence continues to evolve on long-term cardiovascular and cancer risk, especially at higher doses, in older patients, or in patients with specific personal or family histories. Timing matters. Dose matters. Route matters. Patient selection matters. Anyone telling you hormones are completely harmless is simplifying a real medical decision. Anyone telling you the answer is always no is doing the same thing from the opposite side.

That is why consultation matters. Risk review includes personal history, family history, current symptoms, age, time from menopause onset, vascular risk factors, and contraindications such as certain clotting disorders or hormone-sensitive cancers. If BHRT is appropriate, it should be prescribed because the benefit-risk balance makes sense for that individual patient. Not because it is fashionable, and not because someone saw a social media clip that made it sound easy.

What a Hormone Optimization Plan Actually Looks Like

The process starts with consultation and a full lab panel. Not treatment on the first phone call. The protocol is then built around labs, symptoms, goals, and the parts of the case that deserve caution. Delivery method is chosen per patient, not by habit. Some patients do best with estradiol and progesterone only. Some need a broader plan. Some are not hormone candidates at all and are better served by addressing sleep, thyroid function, metabolic dysfunction, or another driver first.

Once treatment begins, follow-up labs are usually checked at six to eight weeks. That matters because early symptom response can be misleading. A patient may feel better but still need dose adjustment. A patient may feel only partly better because thyroid function, cortisol pattern, or insulin resistance is still getting in the way. Hormone work is easier to oversimplify than it is to do well.

After the initial adjustment phase, ongoing monitoring continues, with semi-annual labs at minimum for most patients and closer follow-up when clinically appropriate. Symptom tracking matters, but data matters too. The goal is not just to chase relief in the moment. It is to support mood, sleep, body composition, cognition, sexual health, and long-term function without drifting into careless dosing.

There is another practical point patients appreciate once treatment starts: follow-up is where the real calibration happens. One woman may have excellent relief of hot flashes and still need help with sleep depth or libido. Another may feel emotionally steadier but still be fighting joint pain, vaginal symptoms, or a stubborn metabolic slowdown. That does not mean the plan failed. It means the plan needs refinement, and refinement is part of physician-led care.

At Liondale, hormone optimization does not sit in a silo. Some patients are also exploring broader longevity planning through concierge medicine or the practice's more comprehensive longevity program in NYC. Others may be evaluating whether therapies such as therapeutic plasma exchange or NAD+ IV therapy belong in the same clinical picture. Sometimes hormone optimization is the main intervention. Sometimes it is one piece of a broader plan. The important point is that these decisions are made in context, not stacked together because they sound appealing.

That restraint is part of the value. The job is not to sell the longest treatment list. The job is to decide what actually fits.

Beyond Menopause - Men's Hormonal Health

Hormonal decline is not only a women's issue. Testosterone levels in men tend to fall gradually, often beginning in the 30s and becoming more noticeable in the 50s and 60s. Symptoms can include fatigue, lower libido, muscle loss, slower recovery, reduced mental sharpness, and a mood shift that patients often describe as a flattening of drive. That does not mean every tired man needs testosterone. It does mean the workup should be done correctly.

For men, the lab evaluation usually includes total testosterone, free testosterone, LH, FSH, SHBG, estradiol, prolactin, and PSA where appropriate. The decision-making is different from menopause care because the physiology and risk profile are different. Testosterone replacement in men has its own set of tradeoffs and contraindications. It should be reviewed case by case, not handed out because a patient checked three symptom boxes on a form.

Dr. Bissoon sees both men and women for hormonal health. If your concern is specifically low testosterone, sexual function, recovery, or male aging symptoms, see our men's health program for the dedicated evaluation pathway.

Who This Is For

The best candidates are usually women between 40 and 65 who are in perimenopause or early post-menopause and want a physician-led evaluation rather than a symptom checklist and a generic script. This includes women in surgical menopause, women with premature ovarian insufficiency, and women whose primary care visits have not fully addressed what they are experiencing.

It may also fit the patient who is sleeping poorly, exercising consistently, eating reasonably well, and still feels like her body changed in a way that does not add up. The point is not to medicalize every rough season of life. The point is to investigate when the clinical picture suggests hormones belong in the differential.

This is not for everyone. Patients with active hormone-sensitive cancers, certain clotting or cardiovascular contraindications, uncontrolled medical issues, or other factors that make hormone therapy inappropriate are screened carefully. If hormone therapy is not the right move, Dr. Bissoon says so. Alternatives are discussed. That honesty is part of the standard of care, not a bonus.

If you are wondering whether you are a candidate, the next step is not self-diagnosis through a symptom chart. It is consultation, baseline testing, and a grounded conversation about what the data shows.

FAQ

Am I too young for hormone therapy?

Not necessarily. Some women develop symptoms in their early 40s or even earlier, especially in surgical menopause or premature ovarian insufficiency. Age alone does not answer the question. Timing, symptoms, lab data, menstrual history, and risk profile matter more than a single age cutoff.

Is bioidentical hormone therapy safer than conventional HRT?

It is more accurate to say the conversation is more specific, not automatically safer. Bioidentical estradiol and progesterone are not the same compounds studied in the original WHI trial, so they should not be treated as identical. But that does not make BHRT risk-free. Route, dose, timing, and patient selection still matter, and the long-term evidence continues to evolve.

How long before I feel better on hormones?

Some patients notice changes in a few weeks, especially with sleep, hot flashes, or mood stability. Others take longer. Tissue response is not instant, and dose adjustments are common early on. That is why Liondale rechecks labs and symptoms rather than assuming the first protocol is the final one.

Will I need to take hormones forever?

Not always. Some patients use hormones for a defined period. Others stay on treatment longer because the benefits continue to outweigh the risks. Duration should be reviewed over time, not decided once and never revisited. The right plan at 49 may not be the right plan at 59.

Can I do hormone optimization alongside TPE?

Often, yes, but only if both therapies make sense clinically. Hormone optimization and TPE address different parts of the picture. One is not a substitute for the other. If both are relevant, timing and monitoring should be coordinated so the plan stays clear and measurable.

Does Liondale treat men's hormonal health too?

Yes. Dr. Bissoon evaluates men for low testosterone, symptom-driven hormone decline, and broader men's health concerns. If that is your focus, visit the men's hormonal health page for more detail on the workup and treatment approach.

Does insurance cover this?

Coverage varies, and many hormone optimization programs are at least partly self-pay. Lab work may be covered in some cases, while consultations, compounded medications, pellets, or ongoing monitoring may not be. Liondale discusses the expected structure before treatment so there are fewer surprises.

This page was written and reviewed by Lionel Bissoon, D.O., founder of Liondale Medical. Dr. Bissoon is a board-certified osteopathic physician specializing in anti-aging, hormone optimization, and concierge medicine on the Upper West Side of Manhattan. Note: This page requires Dr. Bissoon's review and sign-off before publication.

This content is for educational purposes only and does not constitute medical advice. Individual results may vary. Specific treatments, dosing, and suitability must be discussed with a qualified physician. Consult your physician before beginning any hormone therapy.